In this retrospective analysis, the overall survival of neoadjuvant treated patients with BRAF-directed therapies followed by surgery (n = 20) was significantly prolonged compared to the patients treated with a BRAF-/MEK-inhibitor combination without tumor resection (n = 35) (1-year survival 94% vs. 52%, p = 0.02) Eight of these 20 patients presented with stage IVC disease [6]. Here, BRAF is linked to neoplasm.